[go: up one dir, main page]

WO1996009066A3 - Method of treatment of human immunodeficiency virus (hiv) infection - Google Patents

Method of treatment of human immunodeficiency virus (hiv) infection Download PDF

Info

Publication number
WO1996009066A3
WO1996009066A3 PCT/US1995/011943 US9511943W WO9609066A3 WO 1996009066 A3 WO1996009066 A3 WO 1996009066A3 US 9511943 W US9511943 W US 9511943W WO 9609066 A3 WO9609066 A3 WO 9609066A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
hiv
immunodeficiency virus
siv
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/011943
Other languages
French (fr)
Other versions
WO1996009066A2 (en
Inventor
Janice E Clements
Michael Murphey-Corb
M Christine Zink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Tulane University
Original Assignee
Johns Hopkins University
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Tulane University filed Critical Johns Hopkins University
Priority to EP95933167A priority Critical patent/EP0784484A2/en
Priority to AU35930/95A priority patent/AU3593095A/en
Publication of WO1996009066A2 publication Critical patent/WO1996009066A2/en
Publication of WO1996009066A3 publication Critical patent/WO1996009066A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating a host prophylactically or therapeutically for infection with human immunodeficiency virus (HIV) is described. A simian immunodeficiency virus (SIV)-macaque monkey model shows that infection with a non-pathogenic, macrophage-tropic, recombinant SIV provides systemic immunity to the host by stimulation of production of neutralizing antibodies. Tests provided show that the neutralizing antibodies produced are broadly reactive with several heterologous strains of SIV. Also provided are pharmaceutical compositions useful for treatment of a subject prior to or following infection with HIV.
PCT/US1995/011943 1994-09-23 1995-09-19 Method of treatment of human immunodeficiency virus (hiv) infection Ceased WO1996009066A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95933167A EP0784484A2 (en) 1994-09-23 1995-09-19 Method of treatment of human immunodeficiency virus (hiv) infection
AU35930/95A AU3593095A (en) 1994-09-23 1995-09-19 Method of treatment of human immunodeficiency virus (hiv) infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31142494A 1994-09-23 1994-09-23
US08/311,424 1994-09-23

Publications (2)

Publication Number Publication Date
WO1996009066A2 WO1996009066A2 (en) 1996-03-28
WO1996009066A3 true WO1996009066A3 (en) 1996-05-23

Family

ID=23206813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/011943 Ceased WO1996009066A2 (en) 1994-09-23 1995-09-19 Method of treatment of human immunodeficiency virus (hiv) infection

Country Status (3)

Country Link
EP (1) EP0784484A2 (en)
AU (1) AU3593095A (en)
WO (1) WO1996009066A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523721A (en) 1998-12-31 2003-08-12 カイロン コーポレイション Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021806A1 (en) * 1993-03-19 1994-09-29 Medical Research Council Delivery system controlled through factors associated with hiv and cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021806A1 (en) * 1993-03-19 1994-09-29 Medical Research Council Delivery system controlled through factors associated with hiv and cell

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERNANDO PLATA ET AL.: "AIDS virus-specific cytotoxic T lymphocytes in lung disorders", NATURE, vol. 328, pages 348 - 351 *
JANICE E. CLEMENTS ET AL.: "Cross-Protective Immune Responses Induced in Rhesus Macaques by Immunization with Attenuated Macrophage-Tropic Simian Immunodeficiency Virus", JOURNAL OF VIROLOGY, vol. 69, no. 5, pages 2737 - 2744 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

Also Published As

Publication number Publication date
EP0784484A2 (en) 1997-07-23
AU3593095A (en) 1996-04-09
WO1996009066A2 (en) 1996-03-28

Similar Documents

Publication Publication Date Title
WO1988009181A3 (en) Monoclonal antibodies neutralizing hiv-1
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
CA2363947A1 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
HK1051317A1 (en) Novel use
GR3023717T3 (en) Process for recovering native domains of viral membrane proteins, their use, in particular as vaccine against hiv.
EP0272858A3 (en) Recombinant hiv envelope proteins produced in insect cells
AU1347688A (en) Viral antigen, process for its production, and application in diagnosis and therapy (vaccine)
EP0306219A3 (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
WO1996009066A3 (en) Method of treatment of human immunodeficiency virus (hiv) infection
AU1226288A (en) Processes for the preparation of medicinal compositions, compositions obtained by these processes and use thereof for the preparation of medicines against viral hepatitis b and acquired immunodeficiency syndrome
WO1990013281A3 (en) Method of suppressing hiv infection
WO1993001820A3 (en) Inhibition of non-cd4 mediated hiv infection
WO2022125378A8 (en) Combination therapy
EP0315459A3 (en) Hiv incomplete particles and a method for production thereof
EP4464380A3 (en) Hiv vaccine immunogens
AP9600896A0 (en) Anti-HIV triple combination.
WO2003089000A3 (en) Anti-hiv composition, production method thereof and medicament
EP0345028A3 (en) Treatment of glaucoma using phosphodiesterase inhibitor
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0093497A3 (en) Anthelmintic treatment
EP0076696A3 (en) A restriction enzyme and a method for production thereof
EP0235904A3 (en) Treatment of allergy with thymopentin
IL139360A0 (en) Viral chimeras comprised of caev and hiv-1 genetic elements
AU3335689A (en) Recombinant gag precursor of hiv, product, process, and use as aids vaccine
GR3003638T3 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995933167

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995933167

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995933167

Country of ref document: EP